Thompson Davis & CO. Inc. Takes $31,000 Position in iCAD, Inc. (NASDAQ:ICAD)

Thompson Davis & CO. Inc. purchased a new position in iCAD, Inc. (NASDAQ:ICAD) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 16,777 shares of the technology company’s stock, valued at approximately $31,000.

Separately, waypoint wealth counsel raised its stake in iCAD by 44.0% in the fourth quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock worth $26,000 after buying an additional 4,400 shares in the last quarter. Hedge funds and other institutional investors own 24.61% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of iCAD from a “sell” rating to a “hold” rating in a report on Thursday.

iCAD Price Performance

Shares of ICAD opened at $2.70 on Friday. The firm has a market capitalization of $71.66 million, a PE ratio of -20.77 and a beta of 1.47. The company’s fifty day moving average price is $2.46 and its 200-day moving average price is $1.93. iCAD, Inc. has a 1-year low of $1.18 and a 1-year high of $3.78.

iCAD Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.